Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/jmph-179

Comprehensive Clinical Perspectives on Upper Respiratory Tract Infections: A Multidisciplinary Focus on the Common Cold

Areej Mohammed Mobarki [(1)] , Amna Aziz Al-Subaie [(1)] , Meaad Yahya Ahmed Machajy [(1)] , Aisha Hassan Ali Maeid [(2)] , Emad Ali Abdu Fagihi [(2)] , Ali Ibraheem Nasser Khlofah Tayash [(3)] , Najla Aidarous Mohammed Mathkour [(3)] , Zainab Mohammed Yahya Mobarki [(4)] , Amnah Mohammed Yahya Mobarki [(4)] , Tahani Aidarous Mohammed Mathkour [(5)] , Laila Aidarous Mohammed Mathkour [(6)]

(1) Imam Abdulrahman Al-Faisal Hospital, Riyadh, Ministry of Health, Saudi Arabia, Saudi Arabia,
(2) Health center, Jazan Health Cluster, Ministry of Health, Saudi Arabia, Saudi Arabia,
(3) Health center, Ahad Al masarihah, Ministry of Health, Saudi Arabia, Saudi Arabia,
(4) Jazan Health Cluster, Ministry of Health, Saudi Arabia, Saudi Arabia,
(5) King Khaled hospital, Tabouk, Ministry of Health, Saudi Arabia, Saudi Arabia,
(6) Samtah General Hospital, Jazan Health Cluster, Ministry of Health, Saudi Arabia, Saudi Arabia

Abstract

Background: Upper Respiratory Tract Infections (URTIs), with the common cold as the prototypical illness, are the most prevalent acute illnesses globally. They are primarily caused by viruses, most commonly human rhinoviruses, and represent a significant source of morbidity, economic burden, and inappropriate antibiotic use.

Aim: This article provides a comprehensive clinical review of URTIs, focusing on the common cold. It aims to detail the etiology, pathophysiology, and evidence-based management strategies, with an emphasis on differentiating viral from bacterial illness and promoting high-value, supportive care.

Methods: A detailed analysis of the virology, epidemiology, and host-pathogen interaction of URTIs is presented. The evaluation and management recommendations are synthesized from clinical evidence, focusing on diagnostic stewardship, pharmacologic and non-pharmacologic symptom relief, and interprofessional collaboration.

Results: The pathophysiology of the common cold is driven by the host's inflammatory response to viral infection, not direct viral cytopathy. Diagnosis is primarily clinical, and laboratory testing is reserved for specific scenarios where results would change management. Treatment is supportive, including analgesics, nasal saline, and limited use of decongestants. Antibiotics are ineffective for uncomplicated viral URTIs. Key to management is patient education on the natural course of illness and clear guidance on warning signs for complications.

Conclusion: Effective management of URTIs hinges on a multidisciplinary, evidence-based approach centered on symptomatic relief, antibiotic stewardship, and patient education to optimize outcomes and reduce the societal burden of this common condition.

Keywords: Upper Respiratory Tract Infection, Common Cold, Rhinovirus, Antibiotic Stewardship, Supportive Care, Symptomatic Management.

1. Introduction

Upper respiratory tract infections (URTIs) represent a heterogeneous group of acute mucosal illnesses involving the nose, paranasal sinuses, nasopharynx, oropharynx, and larynx, with a clinical spectrum that ranges from subtle catarrhal symptoms to more disruptive inflammatory syndromes that impair daily function [1]. Among these entities, the "common cold"—also termed acute nasopharyngitis or acute coryza—remains the prototypical presentation, defined by a self-limited constellation of nasal congestion, rhinorrhea, sneezing, pharyngitis, cough, malaise, and occasionally fever and headache. Although numerous pathogens are capable of producing this syndrome, human rhinoviruses are the most frequent etiology worldwide, a dominance that reflects their remarkable antigenic diversity, efficient person-to-person transmission, and tropism for the upper airway epithelium [1][2]. The ubiquity of this clinical picture belies its biological complexity: even mild symptoms are the outward expression of a tightly choreographed interaction between invading virions and host innate and adaptive immune responses that unfolds across the upper respiratory mucosa. Rhinovirus infection, while classically confined to the upper airway, is not pathobiologically limited to the nasopharynx. Increasing evidence shows that rhinoviruses can extend into the lower respiratory tract, trigger epithelial cytokine cascades, and amplify airway hyperresponsiveness, thereby precipitating exacerbations of asthma and chronic obstructive pulmonary disease (COPD) in susceptible individuals

*Corresponding author e-mail: Areej.alkhateeb1@gmail.com (Areej Mohammed Mobarki).

Receive Date: 29 November 2024, Revise Date: 29 December 2024, Accept Date: 31 December 2024

[2]. Moreover, rhinovirus may serve as a "fellow pathogen," altering mucosal defenses and microbiota niches in ways that facilitate secondary viral or bacterial coinfections throughout both the upper and lower tracts [1][2]. This co-pathogenic potential helps explain why a seemingly benign cold occasionally presages sinusitis, otitis media, or bronchitis, and why targeted prevention and early symptomatic control can have outsized effects in medically vulnerable populations [1][2].

The clinical syndrome of the common cold arises from inflammatory mediators rather than direct cytopathic destruction alone. Nasal obstruction and rhinorrhea reflect vascular engorgement and exudation within the turbinates; sneezing and sore throat derive from sensory nerve activation and pharyngeal mucosal irritation; and cough is often the product of postnasal drip and transient lower airway involvement. Symptom onset is typically abrupt after a short incubation period, peaks within several days, and then resolves over one to two weeks in immunocompetent hosts, although cough may linger due to persistent epithelial sensitivity. These dynamics are mirrored by viral shedding patterns that drive transmission in households, schools, and workplaces, highlighting the importance of hand hygiene, respiratory etiquette, and judicious isolation during the symptomatic peak [1]. URTIs are the most common acute infectious illnesses worldwide, cutting across age, geography, and socioeconomic status [1]. While the majority are self-limiting, the aggregate burden is substantial: they degrade quality of life, disrupt sleep and productivity, and result in missed school and workdays. Importantly, the nonspecific overlap of symptoms across viral etiologies can prompt unnecessary healthcare visits and, in many settings, inappropriate antibiotic prescribing, which contributes to antimicrobial resistance and avoidable adverse drug events [1][3]. In the United States alone, the annual economic cost of URTIs—including direct medical expenditures and indirect losses from absenteeism—is estimated at approximately 60 billion dollars, a figure that underscores the outsized societal impact of conditions often dismissed as trivial [3].



Figure-1: Upper respiratory tract infections.

A comprehensive understanding of URTIs therefore demands more than cataloging causative agents; it requires integrating epidemiology, pathophysiology, and clinical reasoning to distinguish uncomplicated viral disease from presentations that warrant further evaluation. Seasonality and exposure context inform pretest probabilities, with rhinovirus activity peaking in fall and spring in many temperate regions, coinciding with school terms and increased indoor crowding [1][2]. Host factors—age, allergic rhinitis, tobacco smoke exposure, chronic lung disease, and immunocompromise—modulate both susceptibility and clinical course, shaping thresholds for diagnostic testing and follow-up. For instance, an elderly patient with COPD and escalating cough during rhinovirus season may merit closer monitoring for impending exacerbation, whereas a healthy adult with mild congestion may be managed supportively without laboratory evaluation. From a care-delivery standpoint, URTIs and the common cold present a strategic opportunity to practice high-value medicine. Evidence-based counseling on the natural history of illness, expected duration, and symptomatic therapies—analgesics, antipyretics, saline irrigation, and, when appropriate, intranasal antihistamines or anticholinergics—reduces anxiety and reliance on antibiotics while aligning expectations about recovery trajectories [1]. In children, careful attention to hydration, fever control, and avoidance of over-the-counter cough and cold preparations with limited evidence or safety concerns is essential, as is anticipatory guidance regarding warning signs for complications such as acute otitis media or sinusitis. In adults with comorbidities, structured follow-up ensures early detection of secondary bacterial infections or lower airway involvement, particularly in those with asthma or COPD in whom rhinovirus is a well-recognized exacerbating agent [2]. Finally, the common cold's seeming banality should not obscure its role as a driver of healthcare utilization and a catalyst for broader respiratory morbidity. Each encounter offers a chance to reinforce prevention—hand hygiene, vaccination against influenza and other pathogens when indicated, and smoking cessation—and to address social determinants that influence exposure and recovery. By situating rhinovirus and URTIs within this broader clinical and public health context, clinicians can reduce inappropriate antibiotic use, mitigate downstream complications, and direct finite resources toward patients at greatest risk for adverse outcomes, thereby narrowing the gap between the perceived triviality of the common cold and its demonstrable population-level impact [1][2][3].

Etiology

Upper respiratory tract infections (URTIs) and, in particular, the common cold represent the clinical outcomes of infection by a remarkably diverse set of viral and, less commonly, bacterial pathogens. Although the rhinovirus remains the leading cause,

accounting for approximately 50% to 80% of cases globally, many other respiratory viruses share overlapping clinical manifestations, making etiologic differentiation difficult on purely clinical grounds [2]. The multiplicity of pathogens underscores the complexity of URTIs and helps explain their recurrence throughout life, their seasonal fluctuations, and their persistence as the most prevalent acute illnesses worldwide. Rhinovirus, the archetypal etiologic agent, is a non-enveloped, positive-sense, single-stranded RNA virus of the *Picornaviridae* family. It comprises more than 160 recognized antigenic subtypes distributed across three genetic species: RV-A, RV-B, and RV-C. These subtypes frequently co-circulate in communities, with no definitive correlation between specific serotypes and illness severity or seasonality. The lack of durable cross-immunity and the antigenic diversity of rhinoviruses account for the repeated infections experienced throughout life. Transmission occurs predominantly through respiratory droplets, direct contact, or self-inoculation via contaminated fomites. After inoculation, the virus targets epithelial cells of the nasal mucosa, where it binds to intercellular adhesion molecule-1 (ICAM-1) or, less commonly, the low-density lipoprotein receptor, initiating local replication and a cascade of cytokine-mediated inflammation responsible for the hallmark nasal congestion, rhinorrhea, and sore throat [2].

Coronaviruses constitute the second most frequent group of agents implicated in the common cold. Prior to the emergence of highly pathogenic strains such as SARS-CoV, MERS-CoV, and SARS-CoV-2, seasonal coronaviruses (229E, OC43, NL63, and HKU1) accounted for roughly 10% to 15% of URTI cases annually. These enveloped RNA viruses infect epithelial cells of the upper airway, often producing mild, self-limited symptoms indistinguishable from those caused by rhinovirus. However, they may occasionally induce lower respiratory tract disease in infants, elderly adults, and immunocompromised hosts. Their transmission peaks in winter months in temperate climates, paralleling influenza circulation patterns. Adenoviruses, double-stranded DNA viruses from the *Adenoviridae* family, are another notable cause of URTIs. They are transmitted by respiratory droplets, fecal-oral spread, or contact with contaminated surfaces and can cause pharyngoconjunctival fever, acute tonsillitis, or nonspecific coryza. Adenoviruses possess exceptional environmental resilience, which allows prolonged survival on fomites and in water sources, occasionally leading to outbreaks in close-contact environments such as military barracks and daycare centers. Parainfluenza viruses (types 1–4) and influenza viruses are significant contributors to the clinical picture of URTIs, particularly during seasonal epidemics. Parainfluenza viruses, members of the *Paramyxoviridae* family, commonly cause laryngotracheobronchitis (croup) in children, while influenza viruses produce systemic symptoms such as fever, myalgia, and malaise in addition to upper respiratory inflammation. The overlap of influenza infection with other respiratory viruses complicates epidemiologic assessments, and coinfections can exacerbate symptom severity [1][2].

Respiratory syncytial virus (RSV), traditionally associated with bronchiolitis and pneumonia in infants, can also present as a common cold in older children and adults. Its seasonal pattern aligns with colder months, and reinfections throughout life are common due to incomplete immunity. Similarly, enteroviruses (notably enterovirus D68 and coxsackieviruses) and human metapneumovirus have been increasingly recognized as etiologic agents in URTIs, producing overlapping symptoms ranging from mild rhinorrhea to more complicated lower respiratory disease in susceptible hosts. Bocavirus, another member of the *Parvoviridae* family, has been identified in pediatric respiratory infections, often as a coinfecting pathogen whose independent pathogenicity remains under study. In addition to these common viruses, several other pathogens may occasionally manifest as URTI-like illnesses. Measles virus, for example, initially produces catarrhal symptoms resembling the common cold—fever, cough, coryza, and conjunctivitis—before the characteristic exanthem emerges. Enteroviruses, particularly during summer outbreaks, can mimic mild URTIs before causing systemic manifestations such as meningitis or hand-foot-and-mouth disease. The diversity of viral etiologies emphasizes that “the common cold” is not a single disease entity but a shared clinical endpoint arising from numerous infectious insults [1][2].

While viruses account for the overwhelming majority of URTIs, bacterial pathogens can act as primary or secondary invaders, especially when mucociliary clearance is impaired following viral infection. Among these, *Group A beta-hemolytic Streptococcus (Streptococcus pyogenes)* is the most significant bacterial cause of acute pharyngitis. Other streptococcal groups, notably *Group C* and *Group G*, may also produce pharyngitis or nonspecific URTI symptoms. *Mycoplasma pneumoniae*—a cell wall-deficient bacterium—can cause pharyngitis, tracheobronchitis, or atypical pneumonia and is particularly prevalent among school-aged children and young adults. Opportunistic gram-negative bacteria, such as *Moraxella catarrhalis* and *Haemophilus influenzae*, contribute to post-viral bacterial sinusitis, otitis media, and bronchitis. *Streptococcus pneumoniae*, although more commonly associated with lower respiratory tract infections, frequently colonizes the nasopharynx and serves as a secondary pathogen following viral disruption of mucosal barriers. In summary, the etiology of URTIs and the common cold encompasses a complex interplay of viruses and bacteria, with rhinovirus as the predominant pathogen but numerous others

contributing to overlapping symptomatology. The simultaneous circulation of multiple viral subtypes, coupled with the potential for bacterial superinfection, underpins the enormous global incidence and recurrence of these infections. Understanding the etiologic diversity is essential not only for guiding rational diagnostic and therapeutic decisions but also for informing preventive strategies, antibiotic stewardship, and future vaccine development targeting the most prevalent respiratory pathogens [1][2].

Epidemiology

Upper respiratory tract infections (URTIs) remain the most common acute illnesses worldwide, and recent global estimates underscore their extraordinary scale. In 2021, all-cause URTIs excluding COVID-19 accounted for approximately 12.8 billion episodes across all age groups, corresponding to an incidence rate of 162,484 per 100,000 population; mortality was low at 0.2 per 100,000, reflecting the typically self-limited nature of these infections despite their vast ubiquity [4]. Age strongly shapes the epidemiologic profile: children younger than two years experience the highest rates, and children five to nine years record the greatest absolute number of episodes, a pattern that mirrors household transmission dynamics, crowding in schools, and the immunologic naiveté of early life [4]. Although precise pathogen-specific attribution is challenging in routine practice, it is reasonable—given virologic surveillance and clinical experience—to infer that a large fraction of this burden is attributable to rhinovirus, the prototypical cause of the common cold [4]. Rhinoviruses circulate worldwide and cause infections throughout the year yet display characteristic seasonal peaks. Clinical presentations cluster in the fall and spring, temporally distinct from the winter-dominant patterns of influenza, respiratory syncytial virus (RSV), and many coronaviruses, which typically peak during colder months in temperate climates [5]. The factors driving these cycles are incompletely resolved, but ambient humidity and temperature likely modulate viral stability, aerosol dynamics, and host mucosal defenses, producing predictable seasonal oscillations that vary by geography and climate zone [6]. Notably, the clinical severity of rhinovirus infections tends to rise during the winter, an effect plausibly linked to seasonal alterations in host defense—such as impaired mucociliary function and changes in innate immune responsiveness—rather than changes in the virus itself [6]. Asymptomatic infection is common across all seasons, meaning that community transmission can persist even when overt clinical cases appear to wane [7].

Transmission of rhinovirus is efficient and multifactorial. Infection spreads via aerosols and larger respiratory droplets, as well as by contact with contaminated fomites followed by self-inoculation of the nasal or conjunctival mucosa; the relative contribution of these pathways remains uncertain and may vary across settings [8]. Importantly, rhinovirus can persist on environmental surfaces for several days, readily transferring to fingers and enabling indirect spread in homes, schools, and workplaces [8]. The incubation period is short—approximately one to four days—facilitating rapid onset of symptoms after exposure and enabling serial chains of transmission before individuals fully recognize illness [8]. Beyond exposure mechanics, psychosocial and behavioral factors also influence susceptibility: stress, depression, inadequate sleep, tobacco smoking, and poor nutrition are each associated with a higher likelihood of developing symptomatic infection, likely by dampening immune defenses and altering mucosal resilience [1]. These host-level modifiers help explain why infections cluster in specific populations during stressful or resource-limited periods even when community viral circulation is constant. Age-specific epidemiology further illuminates the societal footprint of rhinovirus-associated URTIs. In the general adult population, the incidence of the common cold typically ranges from **two to** five episodes per year, with considerable inter-individual variability [9]. Children, however, function as the principal reservoir, experiencing infection rates roughly four times higher than adults—an expected outcome of dense child-to-child contact in daycare and school environments, developing hygiene practices, and an immune system still calibrating to a broad array of respiratory pathogens [9]. This pediatric predominance not only drives household transmission to caregivers and siblings but also shapes public health strategies that prioritize school-based hygiene measures and parental education about symptom recognition, isolation practices, and appropriate use of healthcare resources [9].

Environmental and structural factors modulate transmission risk on a population level. Consistent with droplet and contact-mediated spread, there is a direct correlation between crowding and the likelihood of acquiring a URTI, with higher attack rates in congregate settings such as classrooms, dormitories, and mass gatherings [10]. Interestingly, despite theoretical expectations regarding air exchange, studies do not demonstrate a clear correlation between URTI incidence and the quality of indoor ventilation, a reminder that hand hygiene, surface disinfection, and behavioral interventions (e.g., staying home when ill) may exert larger effects on rhinovirus transmission than ventilation improvements alone in many real-world contexts [10]. Longstanding beliefs that exposure to cold air directly predisposes individuals to catching a cold have not been supported; while cold weather may coincide with increased cases due to behavioral clustering indoors and seasonal host-defense variation, cold exposure per se is not an independent cause of infection [10]. The intersection of rhinovirus epidemiology with

comorbidity profiles adds further nuance. Although most infections remain mild and self-limited, the same seasonal surges that seed URTIs can precipitate clinically meaningful exacerbations of asthma and chronic obstructive pulmonary disease in vulnerable individuals, contributing to emergency visits and hospitalizations that are not proportionate to the otherwise low mortality of URTIs overall [1]. This divergence—benign course for most, but significant risk for some—underscores why surveillance data, even when aggregated across pathogens, still carry actionable implications for anticipatory care in high-risk groups. It also clarifies why the aggregate burden of URTIs, despite minimal lethality, remains vast in human and economic terms: repeated episodes in children and adults produce absenteeism, caregiver burden, and downstream healthcare utilization for complications and exacerbations.

At the household and community levels, epidemiologic patterns of rhinovirus mirror daily social networks. Young children import infections from classrooms, propagate them to family members, and drive short serial intervals of transmission that sustain ongoing community activity throughout the academic year [9]. In workplaces, peak fall and spring circulation translates into predictable spikes in minor illness and productivity losses, magnified when presenteeism—working while ill—facilitates spread among colleagues. Public messaging that emphasizes early symptom recognition, hand hygiene, respiratory etiquette, and brief self-isolation during peak shedding can blunt these cycles without recourse to antibiotics, which are ineffective for viral URTIs and fuel antimicrobial resistance when used inappropriately [1]. In sum, the epidemiology of URTIs and rhinovirus-associated common cold episodes is defined by immense global frequency, marked seasonality with fall and spring peaks, efficient transmission across multiple routes, and strong modulation by age, behavior, and environmental structure. Despite very low mortality, the cumulative clinical and economic impact is substantial because of the sheer number of episodes and their concentration in children who seed household and community transmission [4][5][7][9]. Mechanistic and meteorologic factors—temperature, humidity, and host defense variation—appear to shape seasonal risk, but remain incompletely delineated, leaving room for future research to refine predictive models and guide targeted interventions [6]. Until then, practical epidemiologic insights already support high-value strategies: prioritize hygiene and behavioral measures where children congregate, anticipate seasonal surges to protect individuals with airway disease, discourage ineffective antibiotic use, and align clinical counseling with the short incubation, frequent asymptomatic carriage, and self-limited course that typify this globally pervasive infection [1][8][10].

Pathophysiology

The pathophysiology of the common cold, primarily caused by rhinovirus infection, involves a complex interplay between viral replication and the host's innate and adaptive immune responses. The incubation period typically ranges from one to four days, during which the virus adheres to and infects the epithelial cells of the nasal and conjunctival mucosa. Following inoculation, rhinoviruses can be readily recovered from the nasopharynx, the primary site of replication and inflammation [1]. Unlike other respiratory viruses such as influenza—which exert direct cytotoxic effects on airway epithelium—rhinoviruses do not cause significant cell necrosis. Instead, the majority of clinical manifestations arise from the host's inflammatory response, which drives the symptoms characteristic of the common cold rather than direct tissue destruction [1]. After binding to intercellular adhesion molecule-1 (ICAM-1) or, in some subtypes, the low-density lipoprotein receptor on nasal epithelial cells, rhinoviruses initiate replication within the superficial mucosa. Viral replication triggers the activation of intracellular signaling cascades, leading to the release of a wide range of proinflammatory cytokines and chemokines, including interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α), and interferons. These mediators recruit neutrophils, lymphocytes, and macrophages to the site of infection, generating mucosal edema and hyperemia that manifest clinically as nasal congestion and rhinorrhea [1]. The inflammatory response also induces vascular permeability, enhancing plasma exudation into the mucosa and resulting in watery secretions that typify early infection [1].

A key biochemical contributor to symptoms is bradykinin, a vasoactive peptide derived from the kinin–kallikrein system, which plays a major role in the onset of sore throat, rhinorrhea, and nasal obstruction [11]. Bradykinin, along with prostaglandins and histamine, increases vascular permeability and sensitizes sensory nerve endings, explaining the characteristic nasal irritation and pain. Elevated concentrations of these mediators correlate with symptom severity, and experimental studies show that their intranasal administration can reproduce cold-like symptoms even in the absence of viral replication. Nasal congestion, one of the earliest and most prominent symptoms, results from the dilation of venous sinusoids within the nasal turbinates, causing engorgement of mucosal tissues and obstruction of airflow [12]. Interestingly, this vascular response may represent an antiviral defense mechanism, as the accompanying increase in nasal blood flow and local temperature may inhibit viral replication and facilitate immune activity [12]. Rhinorrhea occurs concurrently as plasma exudate and glandular secretions increase, reflecting an attempt by the host to mechanically clear viral particles and inflammatory debris from the upper airway. The mechanism of cough associated with the

common cold remains less clearly defined. It is thought to result from heightened airway sensory nerve sensitivity mediated by the upregulation of bradykinins and tachykinins, which stimulate cough receptors in the upper and lower airways [13]. Moreover, postnasal drip—the flow of mucus from the nasopharynx to the oropharynx—can irritate the pharyngeal mucosa, further provoking cough. Some studies also suggest that rhinovirus may directly infect the lower respiratory tract, where it can activate cough reflexes and, in predisposed individuals, exacerbate asthma or chronic obstructive pulmonary disease (COPD) [13].

Systemic symptoms such as malaise, myalgia, and headache are attributed to circulating cytokines and prostaglandins, particularly IL-6 and TNF-α, which influence thermoregulation and nociception in the central nervous system [1]. Although most infections remain localized to the upper airway, rhinovirus RNA has been detected in the lower respiratory tract, bloodstream, and even gastrointestinal tissues, suggesting transient viremia and broader dissemination in some hosts. Furthermore, rhinovirus frequently acts as a co-pathogen, altering mucociliary clearance and local immunity in ways that predispose individuals to secondary bacterial infections (e.g., sinusitis, otitis media, or bronchitis) or facilitate coinfection with other respiratory viruses [2]. The immune response to rhinovirus infection is predominantly humoral, characterized by the production of serotype-specific IgA and IgG antibodies that can neutralize viral particles and limit reinfection. However, protection is only partial and short-lived. Reinfection with the same serotype is possible, and minimal cross-reactivity exists among the more than 160 antigenically distinct rhinovirus serotypes [14]. This remarkable diversity explains why humans experience repeated colds throughout life despite prior exposure. Secretory IgA, produced locally in the nasal mucosa, contributes to mucosal defense but wanes rapidly after infection, further enabling recurrent susceptibility. Beyond humoral responses, innate immunity—particularly the activation of interferon-stimulated genes and antiviral peptides—plays a central role in limiting viral replication and shaping clinical outcomes. Individuals with impaired innate responses, whether due to smoking, stress, sleep deprivation, or chronic disease, tend to experience more severe or prolonged infections [1]. The robust cytokine signaling induced by rhinovirus also influences the broader airway environment, enhancing epithelial expression of adhesion molecules and promoting leukocyte recruitment that can exacerbate chronic airway diseases. In conclusion, the pathophysiology of rhinovirus infection and the common cold reflects a host-driven inflammatory process rather than direct viral cytopathology. Symptoms arise from a combination of vascular congestion, neural sensitization, and cytokine release, each representing a component of the immune system's effort to contain infection. While self-limiting in most cases, this response underlies the morbidity and societal burden associated with URTIs. Furthermore, the virus's extensive serotype diversity, efficient transmission, and capacity to interact synergistically with other pathogens ensure its persistence as the leading cause of respiratory illness across all age groups [1][2][11][12][13][14].

History and Physical

In everyday practice, the common cold is so familiar that most individuals self-diagnose and self-manage without entering the healthcare system. Nevertheless, because upper respiratory tract infections (URTIs) are the most frequent acute illnesses worldwide, even a small fraction of symptomatic people seeking care constitutes a substantial clinical workload. Patients primarily present for symptom relief, counseling on the natural history of disease, and reassurance that serious complications are not evolving. For clinicians, a careful, structured history helps distinguish uncomplicated viral nasopharyngitis from conditions requiring additional testing or targeted therapy, while also identifying red flags and vulnerable hosts who may deteriorate more quickly. A comprehensive history begins by clarifying the timeline of symptom onset, the order in which symptoms appeared, and their current trajectory. Many patients can recall that sore throat was the earliest manifestation, followed one to two days later by watery rhinorrhea and paroxysms of sneezing; nasal obstruction, hoarseness or laryngitic changes, and cough typically develop shortly thereafter. Early systemic complaints such as malaise, headache, myalgias, and low-grade fever often accompany the catarrhal phase. In otherwise healthy adults, symptoms generally peak by days two to four and then steadily recede, with most features resolving by seven to ten days. Cough is a notable outlier and may persist for several weeks because of prolonged epithelial sensitivity and postnasal drip. Establishing this arc helps normalize expectations and reduces unnecessary antibiotic requests, a key stewardship goal in ambulatory care [13][14].

Exposure history provides essential context. Clinicians should document recent ill contacts in the household, daycare, school, dormitory, or workplace; participation in mass gatherings or travel; and the presence of similar symptoms among close contacts. Because children are the principal reservoir for rhinovirus and other cold viruses, inquiry about young family members and their daycare or school attendance is particularly informative. The environment of exposure also matters: crowding, poor hand hygiene, and shared fomites favor transmission, and the fall–spring seasonality of rhinovirus can raise pretest probability even before testing is considered. Equally important are host factors that modify risk and

clinical course. A history of asthma, allergic rhinitis, chronic obstructive pulmonary disease, immunosuppression, pregnancy, or advanced age may lower the threshold for closer follow-up, given the higher risk of lower airway involvement or secondary bacterial complications. Vaccination status, particularly against influenza, helps contextualize overlapping seasonal syndromes. Tobacco use, sleep deprivation, psychosocial stress, and suboptimal nutrition are additional modifiers that may intensify or prolong illness. Symptom characterization should be specific and, when feasible, semi-quantitative to enable comparison over time. Patients can be asked to rate pharyngeal soreness, sinus or facial pain, otalgia, headache, nasal congestion, and cough on simple ordinal scales. The cough merits particular attention: dry or productive quality, diurnal pattern, triggers such as cold air or recumbency, and associated wheeze or chest tightness can suggest lower airway reactivity or early bronchitic features. Dyspnea, pleuritic pain, or sustained fever above typical low-grade ranges warrants closer scrutiny for alternative diagnoses or complications such as bacterial pneumonia or acute sinusitis. Because pharyngitis is often a prominent concomitant complaint, it is vital to explore features that might shift the differential away from viral URTI—for instance, prominent odynophagia without cough, tender anterior cervical lymphadenopathy, tonsillar exudates, or a scarlatiniform rash in a compatible epidemiologic setting. In the United States, pharyngitis drives approximately 6 to 10 million pediatric and more than 5 million adult ambulatory visits annually, so disciplined history-taking helps triage testing and avoid overuse of antibiotics [15][16].

A careful review of systems can uncover early clues to nonviral etiologies or complications. Marked sinus pressure with purulent discharge persisting beyond ten days, severe unilateral facial pain, or “double-worsening” after initial improvement raises suspicion for acute bacterial rhinosinusitis. Ear fullness, otalgia, or conductive hearing changes suggest Eustachian tube dysfunction or early acute otitis media. Prominent conjunctivitis, severe myalgias, or abrupt high fever might point toward influenza rather than rhinovirus. In children, particular vigilance for feeding difficulties, decreased oral intake, and lethargy is important, as these signs can herald dehydration or a more systemic process. Across all age groups, a history of recent antibiotic exposure, chronic sinus disease, or immunodeficiency reshapes the risk calculus for secondary bacterial infection. In sum, the clinical history should not merely catalog symptoms but should integrate exposure, host vulnerability, and the symptom trajectory to construct a probability-based assessment. The coexistence of rhinorrhea and cough strongly favors a common cold etiology and, when coupled with low-grade or absent fever and a typical temporal course, supports conservative management with clear return precautions [17]. At the same time, clinicians should be prepared to pivot when the story departs from this pattern, particularly in high-risk populations or when symptoms escalate rather than abate within the expected timeframe [15][16][17].

Physical Examination

The physical examination in suspected common cold is targeted, efficient, and hypothesis-driven. Most patients with uncomplicated viral URTI have normal vital signs or, at most, a low-grade fever and mild tachycardia commensurate with discomfort. Deviations from this pattern warrant a second look. High fever, tachypnea, hypoxemia, or hemodynamic instability are atypical, raise concern for complications or alternative diagnoses, and justify additional testing or escalation of care. In otherwise stable patients, the examination aims to confirm the clinical impression, exclude serious mimics, and identify early signs of complications that might benefit from timely intervention. Oropharyngeal inspection remains central because pharyngitis is so frequently present. With good lighting and a tongue depressor, the clinician should assess mucosal color, edema, and the presence or absence of exudates; look for petechiae on the soft palate; and evaluate for tonsillar hypertrophy, asymmetry, or fluctuance that might suggest peritonsillar abscess rather than simple viral pharyngitis. Viral URTIs typically produce diffuse erythema without focal purulence; scattered, thin exudates may occur but are less diagnostic than the overall context. Because group A beta-hemolytic Streptococcus (GAS) is the most common bacterial etiology of acute pharyngitis—occurring in roughly 10% to 15% of adults and 15% to 30% of children with sore throat—point-of-care testing or culture should be considered when clinical features and scores such as Centor or McIsaac suggest a higher pretest probability [15][16][18]. The decision to test is not trivial; identifying streptococcal disease guides antibiotic therapy that shortens symptom duration modestly and reduces transmission, while indiscriminate testing can lead to unnecessary antibiotics. The examination of the neck complements this assessment: anterior cervical lymphadenopathy is common in both viral and bacterial pharyngitis, whereas posterior adenopathy, generalized nodes, or supraclavicular nodes should prompt a broader differential that includes mononucleosis, viral exanthems, or other systemic conditions. Palpation of the thyroid can uncover goiter or nodules when hoarseness or dysphagia persists beyond the expected course, although such findings are uncommon in straightforward URTI.

Nasal examination often reveals edematous, erythematous turbinates with copious, watery secretions early in illness that may become thicker with time. The presence of purulence alone is not diagnostic of bacterial sinusitis; rather, the duration and pattern of symptoms, fever profile, and unilateral facial pain guide that judgment. Transillumination of

the sinuses has limited sensitivity but, coupled with frontal and maxillary tenderness, can support clinical impressions when imaging is not indicated. Intranasal crusting, ulcerations, or severe septal tenderness are unusual and should prompt consideration of alternative inflammatory or vasculitic processes if present. Otoscopic examination is especially important in pediatric patients and in adults reporting otalgia or ear fullness. Viral URTIs can precipitate Eustachian tube dysfunction with retracted, hypomobile tympanic membranes and serous effusions. In contrast, acute otitis media manifests as a bulging, erythematous membrane with decreased mobility and sometimes purulent middle ear fluid. Distinguishing these entities prevents both undertreatment of bona fide bacterial otitis and overtreatment of serous effusions that require only symptomatic care. Because rhinovirus and other cold viruses can also prime the middle ear for secondary bacterial infection, a baseline otoscopic evaluation provides a reference for subsequent visits if symptoms worsen [16][17][18].

Pulmonary examination should not be cursory, even when the primary complaint is "just a cold." Auscultation may be entirely normal or reveal scattered upper airway sounds transmitted from the pharynx and nasopharynx. Wheezing, prolonged expiratory phase, or coarse lower airway sounds raise concern for reactive airways, acute bronchitis, or early lower respiratory involvement, especially in patients with asthma or chronic obstructive pulmonary disease. In children, the boundary between URTI and bronchiolitis can blur; tachypnea, intercostal retractions, or hypoxemia should trigger reassessment of the working diagnosis and supportive measures appropriate to lower airway disease. If focal crackles, asymmetric breath sounds, or pleuritic pain are present, bacterial pneumonia must be considered, particularly when accompanied by high fever or systemic toxicity. Percussion and egophony maneuvers add value when bacterial consolidation is suspected but imaging is not immediately available. General inspection and systemic examination round out the evaluation. Conjunctivitis may accompany adenoviral illness; generalized rash with the "three Cs" (cough, coryza, conjunctivitis) and Koplik spots suggests measles rather than a simple cold in the unvaccinated or recently exposed. Oral hydration status, capillary refill, and mental status are crucial in the very young, the very old, and the debilitated, who can decompensate quickly from what appears to be a benign infection. Palpation for spleen enlargement, while not routine, is wise when profound fatigue, posterior adenopathy, or exudative pharyngitis suggests infectious mononucleosis, as activity restrictions and anticipatory guidance differ. The physical examination also informs counseling. When vital signs are stable, lungs are clear, the oropharynx shows mild erythema without exudates, and nasal mucosa is edematous with coryzal secretions, the findings strongly support a viral common cold. In this setting, clinicians can confidently emphasize symptomatic care, expected illness duration, and specific reasons to return, such as persistent fever beyond three days, "double-worsening," progressive unilateral sinus pain, new otalgia with hearing changes, dyspnea, or chest pain. Conversely, when the exam reveals worrisome features—high fevers; tonsillar exudates with tender anterior nodes and absence of cough; otoscopic evidence of acute bacterial otitis media; focal pulmonary findings; or signs of dehydration—additional diagnostics, targeted therapy, or closer follow-up are indicated, and patients should be counseled accordingly, with explicit safety-net instructions and timelines for reassessment [17][18].

Ultimately, history and physical examination remain the cornerstone of evaluating suspected common cold. They allow clinicians to apply probabilistic reasoning, avoid unnecessary laboratory testing and antibiotics, and identify the minority of patients who either have complications or an alternative diagnosis. In a healthcare landscape where URTIs drive millions of visits annually, honing these skills is both clinically and systemically impactful. The coexistence of rhinorrhea and cough, a typical temporal progression from sore throat to nasal symptoms and cough, low-grade fever at most, and benign vital signs collectively make the viral diagnosis more likely and render conservative management safe and appropriate in the majority of cases. At the same time, attention to host factors, careful pharyngeal and otoscopic assessments, and a mindful lung examination ensure that conditions such as group A streptococcal pharyngitis, acute bacterial otitis media, acute bacterial sinusitis, bronchitis, and viral pneumonia are neither missed nor over diagnosed, striking the balance between prudent stewardship and patient safety in the care of URTIs [15][16][17][18].



Figure-2: Most common upper respiratory tract infections.

Evaluation

Approach to Upper Respiratory Infection Diagnostic Testing

Upper respiratory tract infections (URTIs) present a distinctive diagnostic challenge because a wide range of viral and bacterial pathogens produces overlapping clinical syndromes that are clinically indistinguishable in many encounters [19][17]. In routine practice, most URTIs are mild, self-limited illnesses due to respiratory viruses; in the case of the common cold, rhinoviruses and adenoviruses account for the majority of presentations and, crucially, typically do not require confirmatory testing to guide management [17]. Nevertheless, decisions to test are not static; they are shaped by seasonality, circulating epidemics and pandemics, patient age and comorbidities, immune competence, clinical severity, and specific examination findings. During periods of heightened community transmission of influenza or respiratory syncytial virus (RSV), for example, lower thresholds for targeted testing may be reasonable to direct antivirals, infection prevention measures, or cohorting in healthcare settings [22][23]. Likewise, in immunocompromised hosts, infants, older adults, and patients with chronic cardiopulmonary disease, a more proactive diagnostic posture can be justified because test results may alter therapy, disposition, and monitoring intensity [20][21]. Any testing strategy must be anchored to the principle of clinical utility. Sensitivity, specificity, and predictive values matter only to the extent that they change what clinicians do for patients or for public health. Before obtaining a specimen, the central question should be whether the result will meaningfully refine diagnosis, guide treatment, modify infection control, or inform disposition; if not, testing is unlikely to add value beyond clinical judgment and may, paradoxically, generate confusion or downstream harms [20][21][22][23]. Practical considerations—including sample type and quality, time from symptom onset, and laboratory turnaround—also weigh heavily; a highly sensitive assay that reports after the window for effective therapy or isolation has passed may not be useful in real time [20][24].

When to Test and When Not to Test

For the ambulatory patient with a classic, mild-to-moderate common cold—rhinorrhea, nasal congestion, sneezing, pharyngitis, and a dry or minimally productive cough—diagnostic testing is generally unnecessary because management is supportive and outcomes are excellent regardless of the identified virus [17]. In such cases, education about the expected illness trajectory, return precautions, and avoidance of unnecessary antibiotics often delivers more value than a laboratory result. Conversely, several scenarios justify testing. Moderate to severe illness with high fever, significant myalgias, or abrupt onset during influenza season raises suspicion for influenza and may prompt rapid molecular or high-performance antigen testing when results would trigger antiviral therapy and enhanced infection control [22][23][24]. Worsening symptoms after an initial improvement, protracted purulent nasal discharge with severe unilateral facial pain, or clinical features of bacterial otitis media or pneumonia warrant an evaluation for secondary bacterial disease; here, testing is targeted at likely complications rather than at the primary viral cause [17][21]. In children, where etiologic clarification can influence daycare return policies and antibiotic stewardship for otitis media and sinusitis, selective testing of respiratory viruses during community outbreaks can reduce unnecessary antibiotic prescriptions and additional diagnostics [22][25]. In emergency and inpatient settings, identification of specific viruses can refine isolation strategies and cohorting decisions, reduce ancillary testing, and occasionally influence disposition, particularly for high-risk patients [20][23].

Test Modalities, Performance Characteristics, and Turnaround

The last two decades have seen rapid advances in diagnostic technology for URTIs, with the introduction and widespread diffusion of point-of-care antigen assays and nucleic acid amplification tests (NAATs), including multiplex molecular panels capable of detecting numerous viral and some bacterial targets simultaneously [24][17][22][20][23]. The analytic sensitivity and specificity of these platforms vary by pathogen and by manufacturer, and performance is also influenced by specimen type, collection technique, and timing relative to symptom onset. In general, NAATs offer superior sensitivity and specificity compared with antigen assays but may carry longer turnaround times and higher costs; advances in cartridge-based systems, however, now provide rapid, near-patient molecular results in minutes for select pathogens [24]. Antigen assays for influenza and RSV have improved but still exhibit lower sensitivity than NAATs, particularly outside peak season or later in the illness course, necessitating clinical correlation and, when necessary, confirmatory testing in high-stakes scenarios [22][23]. Multiplex respiratory panels promise comprehensive pathogen identification, yet their breadth invites careful reflection about clinical impact. Panels can detect multiple viruses concurrently, and asymptomatic colonization or prolonged shedding may yield positive results that do not explain the current illness, particularly in children and the immunocompromised [20]. This raises the possibility of false assumptions about causality and the risk of overlooking bacterial coinfection when a viral pathogen is identified, a pitfall that underscores the need to interpret results within the clinical context rather than in isolation [17][20]. Timing also matters: sensitivity for many targets is greatest early in illness, often within the first three to five days after symptom onset, when viral loads are highest; testing late may miss the diagnostic window, particularly for antigen assays [22][24]. Thus, clinicians must balance analytic performance

with logistical realities, selecting the right test at the right time for the right patient.

Interpreting Results in Clinical Context

Diagnostic stewardship requires that test results sharpen, rather than blur, clinical reasoning. A positive rhinovirus or seasonal coronavirus result in a patient with classic common cold symptoms lends confidence to supportive management and can curtail unnecessary antibiotic prescriptions, but it does not exclude the possibility of coincident bacterial disease if new, focal findings or "double-worsening" appear later in the course [17][21]. Detection of influenza or RSV in high-risk patients should prompt guideline-concordant antivirals and appropriate infection control precautions, with recognition that negative antigen results do not definitively rule out infection when pretest probability is high; in such cases, reflex molecular testing may be appropriate [22][23][24]. In immunocompromised hosts, identification of pathogens such as adenovirus, human metapneumovirus, or parainfluenza carries greater prognostic weight and may trigger closer monitoring or even pathogen-specific therapies in select contexts [20][23]. Importantly, positive multiplex results for multiple viruses—or a virus plus colonizing bacteria—necessitate careful attribution of symptoms to avoid overtreatment or missed complications. Longitudinal assessment, coupled with targeted physical examination, remains indispensable for discerning evolving sinusitis, otitis media, or lower respiratory tract involvement despite an initial viral diagnosis.

Setting, Resource Utilization, and Workflow

The environment of care dictates what is feasible and valuable. At home, self-tests for influenza and other respiratory viruses are emerging, but their integration into clinical decision-making is evolving and depends on local pathways for confirmatory testing and treatment access [24]. In the outpatient clinic, point-of-care assays with rapid turnaround can influence counseling and reduce unnecessary antibiotics when positive, but they also consume staff time and resources; clinicians must weigh these opportunity costs against expected benefits in their specific practice [20][25]. In emergency departments, rapid molecular testing can streamline isolation decisions, target antivirals, and support safe discharge versus admission, generating potential cost offsets by averting ancillary imaging or laboratory studies and by preventing nosocomial spread [23][24]. On inpatient wards, respiratory panels can assist with cohorting and antimicrobial stewardship, but indiscriminate use may strain laboratory capacity and produce results with limited management consequences for patients already receiving supportive care. For each setting, the central calculus remains whether the result will alter clinical impression, management, or public health action in a timely fashion [20][21][22][23][25].

Overutilization, Stewardship, and the Problem of "More Data"

Multiple investigations have concluded that URTI testing is frequently overutilized, driven by entrenched habits, diagnostic uncertainty, time pressure, and patient expectations for a definitive label [20][22][24][25][21]. While testing can reassure some patients and clinicians, it may also lead to result cascades, incidental findings, or false reassurance that obscures developing bacterial complications. Stewardship principles advocate for targeted testing with a clear purpose: initiate or withhold antivirals, inform infection prevention, guide disposition, or support antibiotic avoidance in circumstances where a documented viral diagnosis changes management [21][25]. Education of clinicians and patients alike is vital. Clear communication that most common colds are viral, self-limited illnesses without an effective pathogen-specific therapy, and that testing seldom accelerates recovery, can realign expectations. At the system level, decision-support tools and testing algorithms aligned with local epidemiology help curb indiscriminate panel use, preserve laboratory capacity during surges, and focus diagnostics on scenarios where they yield tangible benefits.

Patient-Centered Considerations and Equity

Patient experience and equity considerations should inform diagnostic choices. Nasopharyngeal sampling can be uncomfortable, and in pediatrics it may require additional personnel or restraint, which carries emotional and physical costs. Oropharyngeal, mid-turbinate, or anterior nasal swabs may be acceptable alternatives for some assays with validated performance, reducing discomfort without sacrificing accuracy [24]. Cost and coverage also matter out-of-pocket expenses for panels may be substantial, and indiscriminate testing can widen disparities by consuming limited resources that could be directed toward care with clearer benefit. Access to timely results is essential if testing is to influence therapy; marginalized patients disproportionately experience delays that erode the value of even high-quality tests. Incorporating these realities into decision-making respects patient preferences and ensures that diagnostics advance, rather than complicate, equitable care.

A Practical Decision Framework Without Bulleted Checklists

In practice, clinicians can translate the many considerations that appear in guidelines and reviews into a succinct, patient-centered internal dialogue at the point of care. First, define the clinical question: is this an uncomplicated viral URTI that will be managed supportively, or is there reasonable suspicion for a specific pathogen whose identification would alter therapy or infection control [20][21]? Next, consider the epidemiologic context: which pathogens are currently circulating, and does the available test panel reflect this seasonality, acknowledging that positive

and negative predictive values shift with prevalence [22][23][24]? Evaluate the patient context: does the child or adult in front of you possess characteristics—age, pregnancy, immunosuppression, chronic lung or heart disease—that heighten the stakes of a correct and timely diagnosis, or that alter test sensitivity relative to adults [21][22]? Consider timing: is the patient within the window where the assay performs optimally, recognizing that sample quality and collection technique can markedly affect sensitivity [22][24]? Anticipate logistics: how quickly will results return, who will act on them, and will that action plausibly change counseling, therapy, isolation, admission, or discharge [20][23]? Reflect on workflow and cost: will testing slow clinic flow or strain laboratory capacity, and are there cost offsets from preventing unnecessary imaging, hospitalizations, or antibiotics [25]? Finally, weigh patient comfort and preferences: is the sampling method acceptable, and does the patient understand the potential benefits and limitations of the test in the context of their goals and concerns [24][25]?

Approached this way—through purposeful questions embedded in the clinical encounter—diagnostic testing becomes a tool, not a reflex. For the majority of common colds, no test is required; careful history and examination suffice. For those cases in which a result carries clear therapeutic, infection control, or public health consequences, selecting the appropriate test at the optimal time, interpreting it within clinical context, and communicating its meaning transparently to patients ensures that diagnostics enhance care rather than merely add data. Such stewardship aligns with the evolving evidence base and with the core tenets of high-value care in both adult and pediatric populations, across home, outpatient, emergency, and inpatient settings [19][20][21][22][23][24][25].

Treatment / Management

Therapeutic Orientation and General Principles

For the vast majority of upper respiratory tract infections attributable to rhinovirus, no pathogen-directed antiviral therapy exists; consequently, management focuses on alleviating symptoms while the host immune response clears the infection [26][27]. This supportive strategy is anchored in a careful balance between efficacy and safety, particularly because hundreds of over-the-counter (OTC) and behind-the-counter products—often in multi-ingredient combinations—are marketed for the "common cold," yet relatively few have been evaluated in large, methodologically rigorous randomized trials, and even fewer have been adequately tested in children [26]. Across age groups, clinicians should adopt a parsimonious approach, selecting single-ingredient agents that target specific symptoms, avoiding redundant combinations, and counseling patients about dosing schedules to reduce the risk of accidental overdose, toxicities, and drug–drug interactions. Pediatric safety is paramount: OTC "cold" medications should not be administered to children younger than four years because of concerns about safety and the lack of demonstrated efficacy; even in older children, cautious use and caregiver education are essential [26][27][CDC Common Cold Treatment]. Because symptom intensity typically peaks within the first several days of illness and wanes over a week, most therapies are intended for short, time-limited courses. The goals are modest but meaningful: relief of throat pain, reduction of nasal obstruction and rhinorrhea, mitigation of cough that disrupts sleep, and support of hydration and functional status. When counseling patients, clinicians should set expectations about the time course of a self-limited viral illness, provide clear return precautions for evolving complications such as sinusitis, otitis media, or lower airway involvement, and underscore that antibiotics provide no benefit for uncomplicated colds while exposing patients to adverse effects and fueling antimicrobial resistance [18][33][34].



Figure-3: Common Viral pathogens.

Pharmacologic Symptom Relief

Analgesics constitute the backbone of early symptom control. Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) reduce pharyngeal discomfort, myalgias, headache, and fever; topical anesthetics (e.g., benzocaine lozenges or sprays) can provide short-lived relief of sore throat when used as directed [26][27]. Selection among these agents should reflect patient comorbidities and concomitant medications—avoiding NSAIDs in those with peptic ulcer disease or advanced chronic kidney disease, and adhering to total daily acetaminophen limits to prevent hepatotoxicity—while emphasizing that analgesics address comfort rather than hasten recovery. For rhinorrhea, ipratropium bromide administered as a nasal spray offers targeted anticholinergic activity that can reduce watery nasal discharge without substantially altering congestion; anticholinergic side effects are usually local but can include dryness or epistaxis with excessive use [26]. First-generation antihistamines such as diphenhydramine and doxylamine may blunt rhinorrhea through anticholinergic effects and can promote sleep, yet sedation and anticholinergic adverse effects (e.g.,

confusion in older adults, urinary retention in men with prostatic hypertrophy, and exacerbation of narrow-angle glaucoma) limit their use in many patients [26][27]. In contrast, second-generation antihistamines typically confer little benefit for cold-related rhinorrhea absent an allergic component [26].

Adrenergic decongestants relieve nasal obstruction by constricting venous sinusoids within the nasal turbinates, thereby shrinking edematous mucosa and improving airflow. Oral pseudoephedrine can be effective but may provoke insomnia, jitteriness, or blood pressure elevation; it should be avoided or used with caution in individuals with uncontrolled hypertension, significant cardiovascular disease, or those taking monoamine oxidase inhibitors. Topical agents such as oxymetazoline nasal spray act rapidly and often produce dramatic symptomatic relief; however, use beyond three days risks rhinitis medicamentosa, a rebound congestive state that can be challenging to reverse [28]. Counseling about strict duration limits and careful technique (brief courses, lowest effective frequency, and avoidance of repeated dosing throughout the day) mitigates this risk. Zinc lozenges have been studied for the common cold with mixed results; when initiated within the first 24 hours of symptom onset, some formulations may modestly reduce the duration or severity of cough and rhinorrhea, though tolerability and gastrointestinal adverse effects can limit adherence [29]. Patients should be advised to avoid intranasal zinc preparations due to the historical association with anosmia; lozenges, when used, should be taken as directed and discontinued if adverse effects occur. Cough remains one of the most bothersome symptoms yet one of the most therapeutically refractory. Dextromethorphan and codeine—alone or combined with the expectorant guaifenesin—have not demonstrated reliable efficacy in children and lack definitive benefit in adults; safety concerns, including misuse potential and respiratory depression (for codeine), underscore the need for restraint [26][27][30]. Benzonatate's safety and efficacy are not well established, and the drug is not recommended for children younger than ten years; accidental ingestion can be fatal in young children, making secure storage imperative in households where it is prescribed to adults [26][27][30]. Rather than reflexively prescribing antitussives, clinicians should target contributing factors—postnasal drip, nocturnal reflux, or bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease—while employing nonpharmacologic measures to improve sleep.

Nonpharmacologic and Complementary Measures

Nonpharmacologic strategies can meaningfully improve comfort with minimal risk when used correctly. Cool-mist humidifiers and sterile saline nasal drops or sprays help moisten and clear nasal passages, can reduce crusting, and may ease breathing in both adults and children [26][CDC Common Cold Treatment]. Care must be taken to maintain device hygiene to prevent microbial growth; only sterile or distilled water should be used in humidifiers and saline preparations should be commercially prepared or carefully mixed as directed to avoid contamination. Saline nasal irrigation, performed gently with appropriate solutions and clean devices, can decrease nasal symptoms for some patients; instruction on technique and frequency prevents overuse-related irritation. Honey exhibits antitussive properties and may reduce nocturnal cough in children older than one year; randomized trials suggest modest benefits compared with placebo or certain OTC antitussives, likely through demulcent effects and sensory modulation [31][32]. Because of the risk of infant botulism from *Clostridium botulinum* spores, honey must not be given to children younger than one year [31][32][CDC Common Cold Treatment]. Mentholated chest rubs containing menthol, camphor, and eucalyptus oil can provide perceived relief of cough and congestion through trigeminal stimulation and a cooling sensation; however, they can irritate skin, eyes, and nasal mucosa if applied improperly, and accidental ingestion is dangerous, particularly in toddlers [26]. Patients should be counseled on safe application (external use only, away from broken skin or mucous membranes, and out of reach of children). Hydration, rest, and graded return to activity remain foundational. Warm fluids and broths can soothe sore throat and aid hydration, while voice rest and avoidance of irritants such as smoke support mucosal recovery. Patients often inquire about vitamin C, echinacea, and other supplements; the evidence for these agents is heterogeneous and beyond the scope of this discussion, but clinicians can emphasize that no complementary therapy has consistently demonstrated robust clinical benefit across populations and that cost, interactions, and safety profiles should be considered before use [26][27].

Special Populations and Safety Considerations

Management must be individualized for vulnerable groups. In young children, avoidance of OTC multi-ingredient cold medicines under four years is a firm safety recommendation; dosing errors are common, and benefits are unproven [26][27]. For older children, single-ingredient therapies (e.g., weight-based acetaminophen or ibuprofen for pain and fever, saline preparations for congestion) are preferred, with careful caregiver education on labels, concentrations, and dosing intervals. In older adults, anticholinergic antihistamines can precipitate confusion, urinary retention, and falls; decongestants may exacerbate hypertension or arrhythmias, and polypharmacy increases the risk of interactions. Patients with pregnancy should be counseled using up-to-date, pregnancy-specific safety resources, selecting the lowest effective doses for the shortest duration and avoiding systemic decongestants or combination

products unless clearly necessary. For individuals with asthma or COPD, rhinovirus infections frequently precipitate exacerbations; while common cold therapies remain supportive, prompt optimization of inhaled controller medications, early use of short-acting bronchodilators, and low thresholds for follow-up are prudent. In immunocompromised hosts, symptomatic management remains central, but clinicians should maintain vigilance for prolonged courses, secondary bacterial infections, and atypical presentations that may warrant diagnostic testing or escalation of care earlier than in immunocompetent individuals [26][27]. Across all populations, a careful medication reconciliation is essential to avoid duplicative acetaminophen dosing from multiple combination products, hazardous interactions with monoamine oxidase inhibitors or other sympathomimetics, and contraindications related to comorbidities such as glaucoma, prostatic hyperplasia, uncontrolled hypertension, and coronary disease. Clear, written instructions help patients avoid common pitfalls.

Antibiotic Stewardship and Indications for Antibacterial Therapy

Antibiotics confer no benefit in the treatment of uncomplicated common cold and should not be prescribed for this indication. Nevertheless, observational data show that antibiotics are still used in roughly 30% to 40% of self-limited URTIs, a practice that contributes significantly to antimicrobial resistance, exposes patients to adverse effects (e.g., *Clostridioides difficile* infection, allergic reactions), and increases costs without improving outcomes [18][33][34]. Effective stewardship hinges on skilled communication: clinicians should explain the viral nature of the illness, the expected duration of symptoms, and specific milestones of recovery; outline symptomatic strategies; and provide explicit criteria for re-evaluation if certain "red flags" arise. This approach addresses the understandable desire many patients have for "a prescription" while aligning expectations with evidence. Antibiotics do have a role when specific bacterial diagnoses are established or strongly suspected. Group A beta-hemolytic streptococcal pharyngitis, confirmed by appropriate testing in patients with compatible clinical features, warrants antibiotics to reduce symptom duration modestly and prevent transmission, while minimizing the risk of suppurative complications. Selected severe cases of acute otitis media and prolonged or "double-worsening" acute bacterial sinusitis—classically defined by symptoms persisting beyond ten days or significant worsening after an initial improvement—may justify antibacterial therapy, guided by local resistance patterns and guideline recommendations [18]. Importantly, viral-positive respiratory panels do not exclude secondary bacterial disease; clinicians must integrate evolving clinical findings, and when a complication is suspected, treat the complication rather than the primary viral illness.

Communication, Education, and Shared Decision-Making

Because many patients seek medical attention for reassurance and symptomatic relief, the clinical encounter is an opportunity to deliver high-value care through education. Explaining the host-driven pathophysiology of symptoms—nasal vascular engorgement causing congestion, inflammatory mediators producing soreness and malaise—helps patients understand why targeted, short-course therapies are recommended and why antibiotics are not. Shared decision-making can personalize choices among symptomatic options, weighing potential benefits (e.g., improved sleep from a sedating antihistamine) against risks (e.g., next-day cognitive slowing in older adults). Written instructions that summarize dosing schedules, maximum daily limits, and specific signs that should prompt re-evaluation reinforce safety. Caregivers of children benefit from concrete guidance on measuring and administering liquid medications, recognizing dehydration, and timing follow-up if fever or cough persists beyond expected windows. Public health messaging aligns with clinical care. Patients should be encouraged to practice hand hygiene, respiratory etiquette (covering coughs and sneezes, short-term masking during peak symptom days if tolerated), and brief self-isolation while febrile or markedly symptomatic to reduce household and community transmission. For some, particularly those with frequent recurrent infections linked to child-to-child transmission, simple behavioral adjustments—regular surface disinfection of shared devices, attention to sleep and nutrition, and avoidance of tobacco smoke exposure—can reduce future illness frequency.

Putting Practice Principles into Action

In practical terms, treatment plans for adults with an uncomplicated cold might include acetaminophen or an NSAID for pain and fever, saline nasal sprays and brief courses of topical decongestant for severe congestion with strict limits to avoid rebound, ipratropium nasal spray for prominent rhinorrhea, and nonpharmacologic supports such as humidification and hydration. If nighttime cough disrupts sleep, addressing postnasal drip with positional strategies and intranasal therapy may be preferable to antitussives of uncertain efficacy; in adults with persistent troublesome cough, a time-limited trial of an agent such as dextromethorphan can be considered with counseling about modest expected benefit and safety [26][27][30]. In children older than one year, honey at bedtime may ease cough; in all children, caregivers should avoid multi-ingredient OTC cold products under four years and use single-ingredient analgesics and saline measures with precise dosing. Across scenarios, clinicians should revisit the plan if symptoms worsen, fail to improve by ten days, or new focal findings appear that suggest bacterial complications. In summary, management of rhinovirus-associated common cold centers on

judicious, evidence-informed symptomatic care tailored to patient age, comorbidities, and preferences. Pharmacologic options—analgesics, selective anticholinergic or adrenergic nasal therapies, and carefully chosen adjuncts such as zinc lozenges begun early—can ease the burden of illness when used thoughtfully and briefly [26][27][28][29]. Nonpharmacologic measures—humidification, sterile saline, honey in appropriate age groups, and mentholated rubs with attention to application safety—offer additional relief with low risk when applied correctly [26][31][32][CDC Common Cold Treatment]. Equally vital is the disciplined avoidance of unnecessary antibiotics, reinforced by clear, empathetic communication that empowers patients and caregivers to navigate the course of a self-limited viral infection while remaining alert to the minority who develop complications warranting targeted antibacterial treatment [18][33][34]. This coherent, patient-centered framework safeguards individuals from harm, preserves antimicrobial efficacy, and aligns day-to-day practice with the best available evidence.

Differential Diagnosis

Upper respiratory tract infections (URTIs) share many symptoms and often begin abruptly; the common cold is best regarded as a clinical diagnosis characterized by nasal congestion, rhinorrhea, sneezing, sore throat, and a usually dry cough that resolves within 7–10 days, though cough may persist for several weeks. Distinguishing the common cold from mimics relies on the sequence, tempo, and severity of symptoms, exposure context, and targeted testing when results will influence management. Allergic rhinitis typically presents with itchy eyes, clear rhinorrhea, paroxysmal sneezing, and seasonal or exposure-related triggers; fever is absent, and symptoms improve with antihistamines and allergen avoidance. Bacterial pharyngitis (e.g., group A streptococcus) is suggested by abrupt severe sore throat, fever, tender anterior cervical nodes, tonsillar exudates, and absence of cough; confirm with rapid antigen testing or culture, and treat to reduce transmission and complications. COVID-19 can overlap substantially with colds but more often features systemic symptoms (fatigue, myalgias), anosmia/dysgeusia, and variable fever; testing is indicated when results affect isolation or therapy. Influenza tends to have sudden high fever, rigors, prominent myalgias, prostration, and headache, with respiratory symptoms following; antivirals are time-sensitive, so rapid testing during season is useful. Epstein–Barr virus infectious mononucleosis presents with marked fatigue, sore throat, posterior cervical lymphadenopathy, palatal petechiae, and sometimes splenomegaly; heterophile or EBV serologies aid diagnosis. Acute HIV seroconversion may mimic a severe viral syndrome with fever, pharyngitis, rash, and lymphadenopathy; consider in high-risk exposures and test appropriately. Acute bronchitis is characterized by persistent cough (often >2–3 weeks), scant systemic illness, and wheeze; chest examination is otherwise benign, and antibiotics are not indicated in uncomplicated cases. Pertussis should be suspected with paroxysmal cough, inspiratory “whoop,” post-tussive emesis, minimal fever, and prolonged course; confirm with PCR and treat to reduce transmission. Overall, careful attention to chronology, fever pattern, systemic features, epidemiology, and targeted diagnostics permits accurate differentiation and appropriate therapy while avoiding unnecessary antibiotics [18][33][34].

Toxicity and Adverse Effect Management

In children younger than six years, cough and cold medications—both prescription and over-the-counter—pose outsized risks that can eclipse any potential symptomatic benefit. Multi-ingredient formulations are particularly hazardous because they obscure the total cumulative doses of components such as first-generation antihistamines (e.g., diphenhydramine) and oral decongestants (e.g., pseudoephedrine or phenylephrine), increasing the likelihood of inadvertent overdose. Antihistamine toxicity may manifest as anticholinergic delirium (agitation, hallucinations, hyperthermia), tachycardia, urinary retention, and seizures; in severe cases, cardiotoxicity and rhabdomyolysis can occur. Decongestant overdose can precipitate hypertensive crises, arrhythmias, ischemia, and central nervous system excitation or depression. Topical nasal decongestants, if misused for more than a few days, can trigger rebound congestion (rhinitis medicamentosa) that perpetuates a cycle of overuse and worsening symptoms. Codeine and other opioid antitussives should be avoided in pediatrics due to variable metabolism (e.g., CYP2D6 ultra-rapid converters), respiratory depression, and lack of robust efficacy; even in adults, potential harms often outweigh modest benefits. Benzonatate carries unique risks of rapid-onset seizures, arrhythmias, and cardiac arrest with accidental ingestion in young children, underscoring the need for stringent storage out of reach. Toxicity prevention hinges on meticulous caregiver education: use single-ingredient products when necessary, adhere strictly to weight-based dosing for antipyretics, avoid duplicative acetaminophen in combination products, and rely on nonpharmacologic therapies (saline, humidification, honey for children >1 year) as first-line options. Clinicians should review all medications in the home, including herbal and “natural” remedies that can interact with conventional drugs or contain pharmacologically active constituents. When toxicity is suspected—e.g., altered mental status, persistent vomiting, severe headache, chest pain, palpitations, or breathing difficulty—prompt poison control consultation and emergency evaluation are warranted. Finally, inappropriate antibiotic prescribing for self-

limited viral URTIs represents a different but equally serious category of harm: it fosters antimicrobial resistance, provokes adverse drug reactions (e.g., rash, diarrhea, *Clostridioides difficile* infection), and medicalizes a benign illness. Antibiotic stewardship, coupled with clear anticipatory guidance about the expected course of viral symptoms, remains central to minimizing iatrogenic risk across age groups [18][33][34].

Prognosis

The vast majority of upper respiratory tract infections are mild to moderate and self-limited, with a symptomatic arc that peaks within several days and resolves over one to two weeks; cough may persist beyond that window due to airway hypersensitivity. At the population level, however, their cumulative impact is enormous. In 2021, there were an estimated 12.8 billion URTI episodes worldwide (excluding COVID-19) and approximately 19,600 non-COVID-19–related deaths—corresponding to a mortality rate of roughly 0.2 per 100,000 population [4]. Mortality concentrates at the extremes of age: newborns—owing to immunologic immaturity and small airway caliber—and older adults—owing to comorbidities, frailty, and diminished physiologic reserve—bear the greatest risk. Geographically, sub-Saharan Africa exhibits the highest mortality rates, reflecting disparities in access to primary care, vaccination, nutrition, and supportive therapies such as supplemental oxygen. Despite low lethality, morbidity is substantial. URTIs drive absenteeism from school and work, healthcare utilization for reassurance and symptom control, and downstream complications in vulnerable hosts, including asthma and COPD exacerbations that disproportionately contribute to emergency visits and hospitalizations. In children, repeated infections during daycare and early school years are common and generally benign but can impose caregiver burden and episodic sleep disruption; in adults with chronic cardiopulmonary disease or immunosuppression, even a "simple cold" may presage lower respiratory involvement or bacterial superinfection. Prognosis in these groups improves with anticipatory management: early optimization of inhaled controllers in asthma/COPD, prompt evaluation of "double-worsening" sinus symptoms, and supportive measures tailored to hydration and nutrition [18][33][34]. At an individual level, favorable prognostic counseling includes three elements: reassurance about the expected self-limited course; explicit return precautions for red flags (persistent high fever beyond three days, pleuritic chest pain, dyspnea, focal lung findings, unilateral severe facial pain, ear pain with hearing changes); and guidance on evidence-based symptomatic options. At a systems level, public health measures—hand hygiene, respiratory etiquette, and targeted vaccination (e.g., influenza) where applicable—modestly reduce transmission and complications, thereby improving aggregate outcomes. In short, prognosis is excellent for most, but vigilance and supportive infrastructure are essential to protect those at the highest risk while avoiding unnecessary medicalization [18][33][34].

Complications

Although URTIs are typically self-limited, a subset progress to complications that extend illness duration, increase healthcare use, and—in specific populations—raise the risk of severe outcomes. Lower respiratory involvement is the most clinically significant evolution. Viral spread or secondary bacterial infection can produce acute bronchitis, bronchiolitis (especially in infants), or pneumonia; the latter warrants prompt recognition when fever escalates, cough becomes productive with dyspnea, or focal auscultatory findings emerge. Secondary bacterial infections classically follow rhinoviral illness due to transient impairment of mucociliary clearance and mucosal immunity. Acute bacterial sinusitis may be suspected when nasal symptoms persist beyond ten days without improvement, when severe unilateral facial pain and purulent discharge develop, or when "double-worsening" occurs after an initial viral improvement. Acute otitis media, especially in young children, can follow Eustachian tube dysfunction and middle ear effusion; untreated or refractory cases risk mastoiditis, a serious complication characterized by postauricular pain, swelling, and erythema. Exacerbations of chronic airways disease are common. Rhinovirus is a well-recognized trigger for asthma and COPD flares, causing heightened bronchial hyperresponsiveness, increased mucus production, and airflow limitation; these events account for much of the morbidity and occasional hospitalizations linked to otherwise mild URTIs. In older adults and those with multimorbidity, dehydration, delirium, and destabilization of chronic conditions (e.g., heart failure) may accompany febrile viral illness, compounding the clinical burden. Nosocomial complications can arise when hospitalized patients with viral infections receive unnecessary antibiotics (risking *C. difficile* colitis) or when invasive lines and devices are introduced without compelling indications. Prevention and early recognition mitigate these risks. Clinicians should provide pragmatic criteria for re-evaluation—persistent high fever, new focal pain, progressive dyspnea, pleuritic chest pain, ear pain with hearing loss, or severe sinus pressure—and tailor follow-up for patients with asthma, COPD, immunosuppression, or extremes of age. Antibiotics should be reserved for clear bacterial indications, and guideline-concordant therapy should be initiated promptly when such complications are diagnosed. For hospitalized or institutionalized patients, infection prevention measures and careful medication review reduce iatrogenic harms. While most URTI complications are manageable with timely interventions, their impact on quality of life and resource use underscores the value of early, accurate triage and patient education [18][33][34].

Patient Education

Deterrence of unnecessary testing and treatment begins with clinician fluency in diagnostic performance metrics—sensitivity, specificity, and predictive values—of available rapid respiratory assays. Understanding how these metrics vary with community prevalence, specimen type, and time from symptom onset enables judicious test ordering and interpretation. Equally important is communicating to patients that identifying a specific virus rarely alters management of the common cold, which remains supportive; overtesting can yield incidental positives (e.g., asymptomatic shedding) that do not explain current symptoms, potentially leading to confusion or missed bacterial complications. Education should normalize the expected course of a viral URTI: most symptoms improve within seven to ten days, while cough may persist longer due to airway sensitivity. Clinicians can provide concise, written "care plans" that list safe, single-ingredient symptom relievers (e.g., acetaminophen or NSAIDs for pain/fever; saline sprays; brief, carefully limited topical decongestant use) and highlight what to avoid (multi-ingredient OTC products in young children, prolonged topical decongestant use, codeine in pediatrics). Discussing the lack of benefit and tangible harms of antibiotics—adverse reactions, *C. difficile*, resistance—fosters antibiotic stewardship and aligns patient expectations with evidence. For caregivers, precise dosing instructions and demonstrations (e.g., using oral syringes) reduce medication errors; reminders to lock away potentially toxic agents (antihistamines, benzonatate) improve safety. Preventive counseling reinforces hand hygiene, respiratory etiquette (e.g., coughing into the elbow, short-term masking during peak symptoms if tolerated), limited close contact while febrile, and avoidance of tobacco smoke exposure. For individuals with asthma or COPD, action plans should specify when to step up inhaled therapy and when to seek care. Finally, clinicians should be attuned to health literacy and language needs, using teach-back techniques to confirm understanding and tailoring materials to cultural contexts. Effective education not only curbs inappropriate antibiotics and risky medications but also enhances self-management, reduces unnecessary revisits, and improves patient satisfaction with conservative care [33][34].

Enhancing Healthcare Team Outcomes

Optimal management of URTIs—particularly the common cold—depends on coordinated, interprofessional practice that integrates diagnostic stewardship, patient education, and safe symptomatic care. Physicians and advanced practitioners lead probabilistic diagnosis, distinguishing uncomplicated viral illness from conditions warranting testing or targeted therapy. By applying evidence-based criteria for bacterial sinusitis, streptococcal pharyngitis, and otitis media, they uphold antibiotic stewardship and reduce overtreatment. Nurses operationalize these plans at the bedside and in clinics: they triage severity, monitor vital signs and hydration, deliver patient-facing education about medication safety (especially in pediatrics), and identify early signs of complications, relaying changes promptly to prescribers. Pharmacists are pivotal in preventing harm from OTC and prescription products by counseling on single-ingredient selection, screening for duplicative acetaminophen and contraindicated decongestants, detecting drug interactions, and recommending nonpharmacologic alternatives when appropriate. Interprofessional communication aligns messages and prevents mixed instructions that erode adherence. Brief, structured care pathways—standardized handouts, dot phrases in the electronic health record, and shared "viral URTI bundles"—help ensure that every team member reinforces consistent guidance about natural history, red flags, and safe therapies. Case reviews and huddles during respiratory virus seasons enable rapid updates as local epidemiology shifts, ensuring testing algorithms and isolation practices remain appropriate. Embedding clinical decision support (e.g., prompts to avoid antibiotics without bacterial criteria, weight-based pediatric dosing calculators) reduces cognitive load and improves safety at scale. Shared decision-making with patients and families is the final connective tissue of high-functioning teams. When clinicians invite questions, acknowledge symptom burden, and offer concrete strategies for comfort, they build trust—making it easier to decline antibiotics, avoid risky multi-ingredient products, and adopt preventive behaviors. Tracking outcomes—return visit rates, antibiotic prescribing, adverse drug events—provides feedback loops for quality improvement. In aggregate, interprofessional collaboration elevates care from a series of isolated decisions to a coherent system that minimizes harm, conserves resources, and delivers patient-centered, evidence-aligned management of the most common infections in clinical practice [33][34].

Conclusion:

In conclusion, Upper Respiratory Tract Infections, particularly the common cold, are ubiquitous, self-limiting viral illnesses whose management must prioritize evidence-based, supportive care. The cornerstone of treatment is alleviating symptoms through targeted pharmacologic agents like analgesics and short-course decongestants, alongside non-pharmacologic measures such as saline irrigation and hydration. A critical component of care is the disciplined avoidance of antibiotics, which are ineffective against viral pathogens and contribute to antimicrobial resistance. Instead, clinician effort should be directed toward comprehensive patient education, setting clear expectations for the typical 7-10 day illness course and providing specific criteria for re-evaluation should complications like bacterial

sinusitis or pneumonia arise. Ultimately, optimizing outcomes for this high-volume condition requires an interprofessional approach that integrates accurate clinical diagnosis, judicious use of diagnostics, and clear communication. This strategy ensures safe, effective symptom control, upholds the principles of antibiotic stewardship, and empowers patients to manage their illness effectively, thereby mitigating the substantial individual and societal impact of URTIs.

References:

1. Eccles R. Common cold. Front Allergy. 2023;4:1224988.
2. To KKW, Yip CCY, Yuen KY. Rhinovirus - From bench to bedside. J Formos Med Assoc. 2017 Jul;116(7):496-504.
3. Poland GA, Barry MA. Common cold, uncommon variation. N Engl J Med. 2009 May 21;360(21):2245-6.
4. GBD 2021 Upper Respiratory Infections Otitis Media Collaborators. Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2025 Jan;25(1):36-51.
5. Esneau C, Duff AC, Bartlett NW. Understanding Rhinovirus Circulation and Impact on Illness. Viruses. 2022 Jan 13;14(1)
6. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu Rev Virol. 2020 Sep 29;7(1):83-101.
7. Galanti M, Birger R, Ud-Dean M, Filip I, Morita H, Comito D, Anthony S, Freyer GA, Ibrahim S, Lane B, Matienzo N, Ligon C, Rabadan R, Shittu A, Tagne E, Shaman J. Rates of asymptomatic respiratory virus infection across age groups. Epidemiol Infect. 2019 Jan;147:e176.
8. Winther B, McCue K, Ashe K, Rubino JR, Hendley JO. Environmental contamination with rhinovirus and transfer to fingers of healthy individuals by daily life activity. J Med Virol. 2007 Oct;79(10):1606-10.
9. Jaume F, Valls-Mateus M, Mullol J. Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020. Curr Allergy Asthma Rep. 2020 Jun 03;20(7):28.
10. Zitter JN, Mazonson PD, Miller DP, Hulley SB, Balmes JR. Aircraft cabin air recirculation and symptoms of the common cold. JAMA. 2002 Jul 24-31;288(4):483-6.
11. Rees GL, Eccles R. Sore throat following nasal and oropharyngeal bradykinin challenge. Acta Otolaryngol. 1994 May;114(3):311-4.
12. Eccles R. The role of nasal congestion as a defence against respiratory viruses. Clin Otolaryngol. 2021 Jan;46(1):4-8.
13. Jacoby DB. Pathophysiology of airway viral infections. Pulm Pharmacol Ther. 2004;17(6):333-6.
14. Makris S, Johnston S. Recent advances in understanding rhinovirus immunity. F1000Res. 2018;7
15. Vincent MT, Celestin N, Hussain AN. Pharyngitis. Am Fam Physician. 2004 Mar 15;69(6):1465-70.
16. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America. Clin Infect Dis. 1997 Sep;25(3):574-83.
17. Calderaro A, Buttrini M, Farina B, Montecchini S, De Conto F, Chezzi C. Respiratory Tract Infections and Laboratory Diagnostic Methods: A Review with A Focus on Syndromic Panel-Based Assays. Microorganisms. 2022 Sep 16;10(9)
18. Sur DKC, Plesa ML. Antibiotic Use in Acute Upper Respiratory Tract Infections. Am Fam Physician. 2022 Dec;106(6):628-636.
19. Dhaini L, Verma R, Gadir MA, Singh H, Farghaly M, Abdelmutalib T, Osman A, Alsayegh K, Gharib SB, Mahboub B, Suliman E, Konstantinopoulou S, Polumuru SR, Pargi S. Recommendations on Rapid Diagnostic Point-of-care Molecular Tests for Respiratory Infections in the United Arab Emirates. Open Respir Med J. ;18:e18743064319029.
20. Ostrow O, Savlov D, Richardson SE, Friedman JN. Reducing Unnecessary Respiratory Viral Testing to Promote High-Value Care. Pediatrics. 2022 Feb 01;149(2)
21. Bellini T, Fueri E, Formigoni C, Mariani M, Villa G, Finetti M, Marin M, De Chiara E, Bratta A, Vanorio B, Casabona F, Pepino C, Castagnola E, Piccotti E, Moscatelli A. Usefulness of Point-of-Care Testing for Respiratory Viruses in a Pediatric Emergency Department Setting. J Clin Med. Dec 03;13(23)
22. Schreckenberger PC, McAdam AJ. Point-Counterpoint: Large Multiplex PCR Panels Should Be First-Line Tests for Detection of Respiratory and Intestinal Pathogens. J Clin Microbiol. 2015 Oct;53(10):3110-5.
23. Garcia-Rodriguez J, Janvier F, Kill C. Key Insights into Respiratory Virus Testing: Sensitivity and Clinical Implications. Microorganisms. 2025 Jan 02;13(1)
24. Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gonzalez MD, Harrington A, Jerris RC, Kehl SC, Leal SM, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Snyder JW, Telford S, Theel ES, Thomson RB, Weinstein MP, Yao JD. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. Mar 05;

25. Zhang N, Wang L, Deng X, Liang R, Su M, He C, Hu L, Su Y, Ren J, Yu F, Du L, Jiang S. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020 Apr;92(4):408-417.
26. Summerlin J, Eiland LS. The Use and Safety of Cough and Cold Medications in the Pediatric Population. J Pediatr Pharmacol Ther. 2025 Feb;30(1):17-26.
27. DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 01;100(5):281-289.
28. Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997;52(40 Suppl):28-34.
29. Nault D, Machingo TA, Shipper AG, Antiporta DA, Hamel C, Nourouzpour S, Konstantinidis M, Phillips E, Lipski EA, Wieland LS. Zinc for prevention and treatment of the common cold. Cochrane Database Syst Rev. May 09;5(5):CD014914.
30. Costantino RC, Leonard J, Gorman EF, Ventura D, Baltz A, Gressler LE. Benzonatate Safety and Effectiveness: A Systematic Review of the Literature. Ann Pharmacother. 2023 Oct;57(10):1221-1236.
31. Murgia V, Manti S, Licari A, De Filippo M, Ciprandi G, Marseglia GL. Upper Respiratory Tract Infection-Associated Acute Cough and the Urge to Cough: New Insights for Clinical Practice. Pediatr Allergy Immunol Pulmonol. 2020 Mar;33(1):3-11.
32. Cox N, Hinkle R. Infant botulism. Am Fam Physician. 2002 Apr 01;65(7):1388-92.
33. Baillie EJ, Merlo G, Magin P, Tapley A, Mulquiney KJ, Davis JS, Fielding A, Davey A, Holliday E, Ball J, Spike N, FitzGerald K, van Driel ML. Antibiotic prescribing for upper respiratory tract infections and acute bronchitis: a longitudinal analysis of general practitioner trainees. Fam Pract. 2022 Nov 22;39(6):1063-1069.
34. Sun G, Manzanares K, Foley KA, Zhou Y, MacGeorge EL. Antibiotic stewardship with upper respiratory tract infection patients at student health centers: Providers' communication experiences and strategies. Am J Infect Control. 2023 Feb;51(2):154-158